Upstream Bioprocessing Market Size was valued at USD 17.2 Billion in 2022. The Upstream Bioprocessing market industry is projected to grow from USD 20.08 Billion in 2023 to USD 69.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.80% during the forecast period (2024 - 2032). The growing adoption of single-use bioprocessing systems and the increasing implementation of process analytical technology (PAT) are the key market drivers enhancing market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The extensive usage of bioreactors and fermenters in both small- and large-scale bioproduction implies that the utilization of these equipment in upstream bioprocessing is anticipated to surge. A bioprocess's ability to break down contaminants and produce materials like food, feed, chemicals, pharmaceuticals and tissues and organs for use in medicine depends on its bioreactors and fermenters. These devices maintain the correct pH, temperature and an appropriate gas supply, add nutrients for proper growth maintenance and create an ideal environment for cells to multiply.
Over the projected period, several variables are propelling this market segment's expansion and driving the market CAGR. Increasing R&D spending and research efforts are important motivators, besides the many advantages of bioreactors and fermenters. For example, Insud Pharma and Fresenius Kabi signed an agreement in March 2022 wherein Fresenius Kabi will purchase 55% of mAbxience, the Spanish group's fully-fledged worldwide biotech company. This partnership is anticipated to expedite Insud Pharma's biotech division, presenting prospects for mAbxience clients and augmenting its research endeavors. Insured Pharma was scheduled to open a new research and development center in Spain in May 2022, highlighting the substantial investments in R&D activities likely to drive growth in this market segment.
Additionally, growth will be aided by alliances, mergers, acquisitions and collaborations with industry leaders. For instance, a license agreement was signed in May 2022 between Lonza and Adva Biotechnology. Lonza granted Adva access to key intellectual property, facilitating the expansion of automated bioreactors. Lonza also gave Adva a non-exclusive license to use several of its intelligent automation and bioreactor control patents as part of the deal. Due to these advances, the market sector for bioreactors and fermenters is anticipated to rise.
Cell-Free by doing away with the requirement for living cells, bioprocessing streamlines the manufacturing procedure. Biopharmaceutical producers may find this alternative appealing since it can result in cost savings and streamlined operations due to its reduction in complexity. Comparing cell-free bioprocessing to conventional cell-based techniques reveals that the former is more scalable and flexible. It facilitates the quick changes in production scale and the generation of many different biomolecules, including metabolites, proteins and enzymes.
For instance, financing for R&D is concentrated in a few federal departments and agencies, according to the Federal Research and Development (R&D) Financing: FY2022 report published in January 2022. Of the total government R&D funding in FY2021, five agencies received 93.0% of it; the Department of Health and Human Services received 27.6% of it. The largest increases in the R&D budget, amounting to USD 7.7 billion (17.8%), would be allocated to the Health and Human Services department. A situation like this is anticipated to accelerate market expansion because upstream bioprocessing is crucial in creating drugs, vaccines and clinical trials, thus driving the Upstream Bioprocessing market revenue.
Based on Product, the Upstream Bioprocessing market segmentation includes bioreactors/fermenters, cell culture products, bioreactors accessories, filters, bags & containers and others. In 2023, the bioreactors/fermenters segment dominated the market. The segment's dominance can be attributed to the enormous variety of bioreactors and fermenters that are readily available, as well as the widespread use of bioreactors in both large- and small-scale bioproduction. The expansion of this market has also been fueled by the development of automated bioreactors for the safe, economical and compliant manufacture of cell-based products for clinical applications. For example, Eppendorf announced in January 2021 the introduction of BioFlo 720, a bioprocess control station designed for use with single-use bioreactors in pilot and production applications.
The cell culture products category is anticipated to be the fastest growing. The increasing need for high-titer-producing cell cultures is a factor in the segment's rise. Additionally, recombinant Chinese Hamster Ovary (CHO) cell line adoption is significant, driving the category growth as established enterprises offer a cost-effective choice. However, early-stage biotech businesses outsource the CHO cell-based production process to achieve more efficient biomanufacturing in terms of yield and time. Because the employment of patented cell lines has a track record of low regulatory risk and effective commercial production, it offers a high success rate in cell cultivation. The previously described benefits for the businesses involved in the upstream bioprocessing industry have a favorable long-term value proposition.
Based on Workflows, the Upstream Bioprocessing market segment includes cell culture, cell separation and media preparation. In 2023, the cell culture category generated the most income. The segment's expansion can be attributed to the continuous technological progress in cell culture systems, including creating micro-bioreactors that enable small-scale bioproduction. The domains of biological data analysis and data management have advanced, offering vital quality qualities associated with cell culture. Ongoing advancements in multi-bioreactor system development and high throughput analytics have driven the revenue in this category.
The upstream bioprocessing cell separation segment is anticipated to grow fastest during the forecast period because of the market's limited acceptance and penetration. Furthermore, features like the usage of flocculants to increase centrifugation process throughput and the single-use tubular bowl centrifugation process are likely to support market expansion.
Based on Use Type, the Upstream Bioprocessing market segmentation includes multi-use and single-use. The multi-use category leads the market because commercial biomanufacturing uses a large number of conventional stainless-steel bioreactors. In addition, these systems have a lower environmental impact than single-use systems and a lower danger of leakage during cell culture procedures. Stainless-steel bioreactors are advantageous when the process scale varies reliably over an extended period with few variations, according to an article published in the European Pharmaceutical Manufacturer.
During the projection period, the upstream bioprocessing market’s single-use segment is anticipated to grow fastest. Single-use products' ability to save money is why the segment is rising. Disposable solutions eliminate the requirement for cleaning or sterilizing procedures, which lowers the additional costs associated with the assembly, maintenance, validation of the process and sterilization procedures necessary for multi-use assemblies.
Based on Mode, the Upstream Bioprocessing market segmentation includes in-house and outsourced. The in-house category leads the market. The most well-known companies that favor in-house manufacturing are the reason behind the dominance of the in-house segment. For many companies, outsourcing entails losing strategic control over the process and having insufficient managerial monitoring. Additionally, these manufacturers employ cross-functional teams to carry out sophisticated production methods in the manufacturing of biopharmaceuticals. The planning and decision-making process for manufacturing biopharmaceuticals has also become more complex due to outsourcing tasks in an attempt to reduce costs. Because of this, large pharmaceutical companies typically stick to their internal facilities when producing biopharmaceuticals.
The outsourced segment of the upstream bioprocessing market is predicted to develop at the quickest rate over the projected period. Bioproduction is now more economical and efficient largely due to the diversification of contract manufacturing services offered. This is especially true for newer and smaller organizations with tighter budgets. These organizations view CMOs as an effective way to deal with their capital and resource constraints.
Figure 1: Upstream Bioprocessing Market, by Mode, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Upstream Bioprocessing market area will dominate this market. The upstream bioprocessing market is expanding due to regional players' initiatives. For example, in November 2021, Bionova launched a USD 25.0 million single-use facility with a 1,000 L Cytiva XDR upstream train in Fremont, California. Additionally, by Q3 of 2022, the business plans to install a 2,000 L Cytiva system. It is anticipated that these advancements will propel market expansion.
Therefore, factors like rising R&D spending, large-scale manufacturing facilities, the rising popularity of disposables, rising healthcare expenses and well-established healthcare infrastructure are expected to contribute to North America's growth in the upstream bioprocessing market.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea and Brazil.
Figure 2: UPSTREAM BIOPROCESSING MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Upstream Bioprocessing market accounts for the second-largest market share because the biopharmaceutical business in Europe is well-established, with a significant concentration of top pharmaceutical corporations, biotech companies and research institutions. Thanks to this well-established industry infrastructure, upstream bioprocessing activities can flourish on a firm foundation. Further, the German Upstream Bioprocessing market held the largest market share and the UK Upstream Bioprocessing market was the fastest-growing market in the European region.
The Asia-Pacific Upstream Bioprocessing Market is expected to grow at the fastest CAGR from 2024 to 2032. Asia Pacific nations, particularly China, India, South Korea and Singapore, have invested largely in the manufacturing, research and development of biopharmaceuticals. The main drivers of this expenditure are the increased need for healthcare, the incidence of chronic illnesses and government programs to support biotechnology and innovation. Moreover, China’s Upstream Bioprocessing market held the largest market share and the Indian Upstream Bioprocessing market was the fastest-growing market in the Asia-Pacific region.
The industry's leading players will continue investing heavily in R&D to expand their Use Type ranges, propelling the Upstream Bioprocessing market's growth. Significant market developments include contractual agreements, mergers and acquisitions, increased investments, collaboration with other organizations and new product releases. Market players are also taking various calculated risks to increase their worldwide reach. It must offer reasonably priced varieties for the Upstream Bioprocessing industry to expand and prosper in a more competitive and dynamic market.
One of the main strategies manufacturers use in the worldwide Upstream Bioprocessing market to benefit customers and expand the market sector is local manufacturing to reduce operating expenses. Some of the biggest medical benefits in recent years have come from the Upstream Bioprocessing sector. Major players in the Upstream Bioprocessing market, including Thermo Fisher Scientific Inc., GE HealthCare, Sartorius AG, Eppendorf AG, Merck KGaA, Corning, Inc., Danaher, PBS Biotech, Inc., Lonza, Boehringer Ingelheim GmbH, Applikon Biotechnology, CellGenix GmbH, AGC Inc. and others, are attempting to increase market demand by investing in research and development operations.
Thermo Fisher Scientific Inc. (Thermo Fisher) supplies tools for medicine, analytical equipment, consumables and reagents, software and services for handling difficult analytical problems in clinical, research and diagnostic labs. It provides answers for synthetic biology, flow cytometry and cellular biology. Products from the company include technologies for molecular biology, genetic sequencing, electron microscopy, protein analysis and mass spectrometry. The company provides services to the environmental, industrial quality and process control sectors, pharmaceutical and biotech industries, academic and research institutions, clinical diagnostic labs, government agencies and so on. Thermo Fisher Scientific expanded its single-use technology production facility in Millersburg, Pennsylvania, in February 2022 with an investment of USD 40 million. This growth is a component of the business's multi-year, USD 650 million investment strategy to strengthen its ability to offer dependable, scalable and adaptable bioprocessing production solutions.
Science and technology are the focus of Merck KGaA (Merck), a division of E. Merck KG. In addition to developing liquid crystal mixes, organic light-emitting diode (OLED) materials, cosmetic active ingredients, coating pigments and high-tech materials, it also finds, develops and produces prescription medications for treating cancer, multiple sclerosis and infertility. Additionally, Merck offers many products, including flow cytometry kits and instruments, end-to-end systems, test assays, analytical reagents, gene editing tools, cell lines, antibodies and microbiological and biomonitoring products. The business services the life sciences, performance materials and healthcare sectors. A non-binding Memorandum of Understanding (MoU) was signed in May 2023 by Merck KGaA, the South Korean Ministry of Trade and Daejeon City, Industry and Energy (MOTIE) to establish a new bioprocessing plant for the Asia-Pacific region. The proposed bioprocessing facility aims to assist the healthcare ecosystem in the area and make it easier for clients in the region to purchase pharmaceuticals and biotech products commercially manufactured.
September 2023: Getinge introduced AppliFlex ST GMP, an advanced single-use bioreactor intended for mRNA production and clinical production of gene and cell treatments. This strategic move is anticipated to assist the business in expanding its range of products and breaking into undiscovered markets.
April 2023: To facilitate upstream bioprocessing procedures for single-use, Cytiva introduced X-platform bioreactors. With this launch, the company increased income and set itself apart from rivals by providing cutting-edge solutions.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 17.2 Billion |
| Market Size 2023 | USD 20.08 Billion |
| Market Size 2032 | USD 69.5 Billion |
| Compound Annual Growth Rate (CAGR) | 16.80% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors and Trends |
| Segments Covered | Product, Workflow, Use Type, Mode and Region |
| Geographies Covered | North America, Europe, Asia Pacific and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea and Brazil |
| Key Companies Profiled | Â Thermo Fisher Scientific Inc., GE HealthCare, Sartorius AG, Eppendorf AG, Merck KGaA, Corning, Inc., Danaher, PBS Biotech, Inc., Lonza, Boehringer Ingelheim GmbH, Applikon Biotechnology, CellGenix GmbH and AGC Inc. |
| Key Market Opportunities | Increasing biomolecules and biosimilars and the biopharmaceutical pipeline have expanded. |
| Key Market Dynamics | Growing adoption of single-use bioprocessing systems and Increasing the implementation of process analytical technology (PAT) |
Frequently Asked Questions (FAQ) :
The Upstream Bioprocessing market size was valued at USD 20.08 Billion in 2023.
The market is projected to grow at a CAGR of 16.80% during the forecast period, 2024-2032.
North America had the largest share of the market
The key players in the market are Thermo Fisher Scientific Inc., GE HealthCare, Sartorius AG, Eppendorf AG, Merck KGaA, Corning, Inc., Danaher, PBS Biotech, Inc., Lonza, Boehringer Ingelheim GmbH, Applikon Biotechnology, CellGenix GmbH and AGC Inc.
The Bioreactors/Fermenters category dominated the market in 2023.
The In-house had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
